Date of Award
Spring 5-17-2024
Document Type
Open Access Thesis
Degree Name
Master of Medical Science (MMSc)
First Advisor
Nicola Santoro, MD, PhD
Abstract
Metabolic dysfunction-associated steatohepatitis is a severe form of liver disease marked by fat accumulation, inflammation, and scarring, often advancing to cirrhosis. Currently, there are limited therapies to treat this condition. Empagliflozin, a Sodium-glucose cotransporter 2 Inhibitor, that blocks renal reabsorption of glucose, has shown efficacy in reducing liver fat accumulation. However, there are currently no large-scale studies have investigated the effect of empagliflozin in treating metabolic dysfunction-associated steatohepatitis using histological findings. We propose a randomized controlled trial to study the effect of empagliflozin on the resolution of Metabolic dysfunction-associated steatohepatitis. We will recruit participants with histology-confirmed metabolic dysfunction-associated steatohepatitis and reassess the resolution of liver histology after 48 weeks of empagliflozin intervention This study aims to increase our knowledge about the effectiveness of empagliflozin in treating metabolic dysfunction-associated steatohepatitis which can reduce the morbidity and mortality caused by the disease.
Recommended Citation
Liu, Peilin Austin, "Effect of Empagliflozin in Adult Patients with Metabolic Dysfunction-Associated Steatohepatitis" (2024). Yale School of Medicine Physician Associate Program Theses. 209.
https://elischolar.library.yale.edu/ysmpa_theses/209
Comments
This is an open access thesis.